Needham analyst Mayank Tandon maintains Perficient (NASDAQ:PRFT) with a Buy and raises the price target from $110 to $130.
Wells Fargo Downgrades Applied Genetic to Equal-Weight, Lowers Price Target to $0.5
Wells Fargo analyst Yanan Zhu downgrades Applied Genetic (NASDAQ:AGTC) from Overweight to Equal-Weight and lowers the price target from $12 to $0.5.